[Form 4] Clorox Company Insider Trading Activity
Eric H. Reynolds, Executive Vice President and Chief Operating Officer of The Clorox Company (CLX), reported transactions dated 09/04/2025. The filing shows an exercise of stock options (derivative) to acquire 15,210 shares at an exercise/conversion price of $111.60, and a related non-derivative acquisition of 15,210 shares (reported at $111.60). The report also discloses a sale of 15,041 shares at a weighted average price of $123.7848 (trade prices ranged $123.731–$123.84). Following these transactions the reporting person is shown as beneficially owning 69,262 shares after the acquisition and 54,221 shares after the sale. The form is signed by an attorney-in-fact on 09/08/2025.
Eric H. Reynolds, Executive Vice President e Chief Operating Officer di The Clorox Company (CLX), ha segnalato operazioni datate 04/09/2025. La comunicazione indica l'esercizio di opzioni su azioni (derivato) per acquisire 15.210 azioni a un prezzo d'esercizio di $111,60 e la corrispondente acquisizione non derivata di 15.210 azioni (valutate a $111,60). Il rapporto riporta inoltre la vendita di 15.041 azioni a un prezzo medio ponderato di $123,7848 (i prezzi di negoziazione sono variati da $123,731 a $123,84). Dopo queste operazioni, il dichiarante risulta titolare beneficiario di 69.262 azioni dopo l'acquisizione e di 54.221 azioni dopo la vendita. Il modulo è firmato da un procuratore il 08/09/2025.
Eric H. Reynolds, Vicepresidente Ejecutivo y Director de Operaciones de The Clorox Company (CLX), informó transacciones con fecha 04/09/2025. El registro muestra el ejercicio de opciones sobre acciones (derivado) para adquirir 15.210 acciones a un precio de ejercicio de $111,60, y la correspondiente adquisición no derivada de 15.210 acciones (registradas a $111,60). El informe también revela la venta de 15.041 acciones a un precio medio ponderado de $123,7848 (los precios de operación oscilaron entre $123,731 y $123,84). Tras estas operaciones, la persona informante posee de forma beneficiaria 69.262 acciones después de la adquisición y 54.221 acciones después de la venta. El formulario está firmado por un apoderado el 08/09/2025.
Eric H. Reynolds, The Clorox Company(CLX) 부사장 겸 최고운영책임자(Executive Vice President and COO)는 2025-09-04자 거래를 보고했습니다. 제출서류에는 주식옵션(파생상품) 행사로 15,210주를 행사가격 $111.60에 취득한 내용과, 이에 따른 비파생 취득 15,210주(보고가 $111.60)가 기재되어 있습니다. 또한 평균 가중 매각가격 $123.7848로 15,041주를 매도한 사실(거래가격 범위 $123.731–$123.84)도 공개되어 있습니다. 이 거래들 후 보고인은 취득 후 69,262주, 매도 후 54,221주의 실질적 보유자로 기재되어 있습니다. 양식은 대리인이 2025-09-08에 서명했습니다.
Eric H. Reynolds, Vice‑Président Exécutif et Chief Operating Officer de The Clorox Company (CLX), a déclaré des opérations datées du 04/09/2025. Le dépôt indique l'exercice d'options sur actions (dérivé) pour acquérir 15 210 actions à un prix d'exercice de 111,60 $, ainsi que l'acquisition non dérivée correspondante de 15 210 actions (déclarées à 111,60 $). Le rapport mentionne également la vente de 15 041 actions à un prix moyen pondéré de 123,7848 $ (prix de transaction compris entre 123,731 $ et 123,84 $). Après ces opérations, la personne déclarante détient à titre bénéficiaire 69 262 actions après l'acquisition et 54 221 actions après la vente. Le formulaire est signé par un mandataire le 08/09/2025.
Eric H. Reynolds, Executive Vice President und Chief Operating Officer der The Clorox Company (CLX), meldete Transaktionen vom 04.09.2025. Die Einreichung zeigt die Ausübung von Aktienoptionen (Derivat) zum Erwerb von 15.210 Aktien zu einem Ausübungspreis von $111,60 sowie den dazugehörigen nicht-derivativen Erwerb von 15.210 Aktien (gemeldet zu $111,60). Der Bericht offenbart außerdem den Verkauf von 15.041 Aktien zu einem gewichteten Durchschnittspreis von $123,7848 (Handelspreise zwischen $123,731 und $123,84). Nach diesen Transaktionen besitzt die meldende Person begünstigt 69.262 Aktien nach dem Erwerb und 54.221 Aktien nach dem Verkauf. Das Formular wurde am 08.09.2025 von einem Bevollmächtigten unterschrieben.
- None.
- None.
Insights
TL;DR: Insider exercised options and sold a roughly equal blocking of shares the same day, leaving mid-five-figure holdings.
The filing documents a simultaneous option exercise and market sale on 09/04/2025. The exercise converted options covering 15,210 shares at a strike of $111.60, which increased beneficial ownership to 69,262 shares before an executed sale of 15,041 shares at a weighted average of $123.7848. The sale prices ranged narrowly ($123.731–$123.84), indicating execution across multiple trades. For investors, this is a routine Section 16 disclosure showing liquidity-taking after option exercise rather than an unambiguous signal about company fundamentals.
TL;DR: Disclosure appears complete for the transactions reported; form is signed by an attorney-in-fact as permitted.
The Form 4 includes required fields: reporting person identity, relationship (EVP & COO), transaction dates, codes, quantities, prices, and an explanatory note on trade price range. The derivative section shows the exercised option details including original exercisability/expiration dates. The signature by an Attorney-in-Fact (Cheryl Brice) on 09/08/2025 is presented. No omissions or inconsistencies are apparent within the form’s content provided.
Eric H. Reynolds, Executive Vice President e Chief Operating Officer di The Clorox Company (CLX), ha segnalato operazioni datate 04/09/2025. La comunicazione indica l'esercizio di opzioni su azioni (derivato) per acquisire 15.210 azioni a un prezzo d'esercizio di $111,60 e la corrispondente acquisizione non derivata di 15.210 azioni (valutate a $111,60). Il rapporto riporta inoltre la vendita di 15.041 azioni a un prezzo medio ponderato di $123,7848 (i prezzi di negoziazione sono variati da $123,731 a $123,84). Dopo queste operazioni, il dichiarante risulta titolare beneficiario di 69.262 azioni dopo l'acquisizione e di 54.221 azioni dopo la vendita. Il modulo è firmato da un procuratore il 08/09/2025.
Eric H. Reynolds, Vicepresidente Ejecutivo y Director de Operaciones de The Clorox Company (CLX), informó transacciones con fecha 04/09/2025. El registro muestra el ejercicio de opciones sobre acciones (derivado) para adquirir 15.210 acciones a un precio de ejercicio de $111,60, y la correspondiente adquisición no derivada de 15.210 acciones (registradas a $111,60). El informe también revela la venta de 15.041 acciones a un precio medio ponderado de $123,7848 (los precios de operación oscilaron entre $123,731 y $123,84). Tras estas operaciones, la persona informante posee de forma beneficiaria 69.262 acciones después de la adquisición y 54.221 acciones después de la venta. El formulario está firmado por un apoderado el 08/09/2025.
Eric H. Reynolds, The Clorox Company(CLX) 부사장 겸 최고운영책임자(Executive Vice President and COO)는 2025-09-04자 거래를 보고했습니다. 제출서류에는 주식옵션(파생상품) 행사로 15,210주를 행사가격 $111.60에 취득한 내용과, 이에 따른 비파생 취득 15,210주(보고가 $111.60)가 기재되어 있습니다. 또한 평균 가중 매각가격 $123.7848로 15,041주를 매도한 사실(거래가격 범위 $123.731–$123.84)도 공개되어 있습니다. 이 거래들 후 보고인은 취득 후 69,262주, 매도 후 54,221주의 실질적 보유자로 기재되어 있습니다. 양식은 대리인이 2025-09-08에 서명했습니다.
Eric H. Reynolds, Vice‑Président Exécutif et Chief Operating Officer de The Clorox Company (CLX), a déclaré des opérations datées du 04/09/2025. Le dépôt indique l'exercice d'options sur actions (dérivé) pour acquérir 15 210 actions à un prix d'exercice de 111,60 $, ainsi que l'acquisition non dérivée correspondante de 15 210 actions (déclarées à 111,60 $). Le rapport mentionne également la vente de 15 041 actions à un prix moyen pondéré de 123,7848 $ (prix de transaction compris entre 123,731 $ et 123,84 $). Après ces opérations, la personne déclarante détient à titre bénéficiaire 69 262 actions après l'acquisition et 54 221 actions après la vente. Le formulaire est signé par un mandataire le 08/09/2025.
Eric H. Reynolds, Executive Vice President und Chief Operating Officer der The Clorox Company (CLX), meldete Transaktionen vom 04.09.2025. Die Einreichung zeigt die Ausübung von Aktienoptionen (Derivat) zum Erwerb von 15.210 Aktien zu einem Ausübungspreis von $111,60 sowie den dazugehörigen nicht-derivativen Erwerb von 15.210 Aktien (gemeldet zu $111,60). Der Bericht offenbart außerdem den Verkauf von 15.041 Aktien zu einem gewichteten Durchschnittspreis von $123,7848 (Handelspreise zwischen $123,731 und $123,84). Nach diesen Transaktionen besitzt die meldende Person begünstigt 69.262 Aktien nach dem Erwerb und 54.221 Aktien nach dem Verkauf. Das Formular wurde am 08.09.2025 von einem Bevollmächtigten unterschrieben.
